Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

4.160 +0.040 (+0.97%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
Recursion Pharmaceuticals (RXRX) CEO Sells 100,000 Shares ↗
Via The Motley Fool
News headline image
Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025
The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock ↗
Recursion is about to go toe-to-toe with the largest healthcare company. 
Via The Motley Fool
Topics Animal Testing Artificial Intelligence
News headline image
AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures
A groundbreaking $2 million grant from the National Institutes of Health (NIH) is set to dramatically accelerate advancements in gene-editing technology, with artificial intelligence (AI) emerging as... 
Via TokenRing AI
Topics Artificial Intelligence Climate Change Intellectual Property
News headline image
Nvidia's AI Reign: A $5 Trillion Bellwether Shaping Wall Street's Fortunes
Nvidia's (NASDAQ: NVDA) recent stock performance has been a whirlwind of soaring highs and sharp corrections, acting as a potent barometer for the broader Wall Street landscape as of November 11, 2025.... 
Via MarketMinute
Topics Artificial Intelligence Economy Law Enforcement
News headline image
Recursion Pharmaceuticals (NASDAQ:RXRX) Reports Q3 2025 Results with Revenue Miss and Extended Cash Runway ↗
Recursion's Q3 2025 results show a major revenue miss and widening loss, but the company highlights strong partnerships and a cash runway into 2027. 
Via Chartmill
News headline image
Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Announces CEO Transition Plan to Drive Next Phase of Growth
Co-Founder and CEO Chris Gibson to Transition to Chairman of the Board; Najat Khan to be named Chief Executive Officer and President 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential
The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
3 Things Investors Need to Know About Recursion Pharmaceuticals ↗
Can this under-the-radar stock be a great way to cash in on AI? 
Via The Motley Fool
Topics Animal Testing Artificial Intelligence
News headline image
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
The AI Imperative: Why Rapid Upskilling is Non-Negotiable for Pharma’s Future
The pharmaceutical sector stands at the precipice of a profound transformation, driven by the relentless march of artificial intelligence (AI) and other advanced technologies. As highlighted by... 
Via TokenRing AI
Topics Artificial Intelligence Economy
News headline image
AI Revolutionizes Pharma R&D: A New Era of Accelerated Drug Discovery and Personalized Medicine
Artificial intelligence (AI) is ushering in a transformative era for pharmaceutical research and development (R&D), fundamentally reshaping how new medicines are discovered, developed, and brought to... 
Via TokenRing AI
Topics Artificial Intelligence Intellectual Property
News headline image
Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? ↗
Recursion uses artificial intelligence to help advance drug discovery, which could be a massive opportunity in healthcare. 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
AI Revolutionizes Drug Discovery and Personalized Medicine: A New Era of Healthcare
The pharmaceutical and biotechnology industries are undergoing a profound transformation, driven by an urgent need for more efficient drug discovery and development processes and the paradigm shift... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence
News headline image
Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th
Company to host public (L)earnings call on November 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMT 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks ↗
Here's a look at the most heavily shorted stocks in the market as investors look for the next Beyond Meat. 
Via Benzinga
News headline image
Short Squeeze Frenzy Fuels October's Market Rebound: A Closer Look at Bearish Bets and Bullish Surges
The U.S. stock market has staged a remarkable recovery in October 2025, with major indices reclaiming lost ground amidst a confluence of positive corporate earnings and improving macroeconomic... 
Via MarketMinute
Topics Economy Stocks World Trade
News headline image
Up 25% in 1 Month, Is This Stock a Buy? ↗
It might look like this beaten-down AI-focused company is finally bouncing back, but don't be too quick to pull the trigger. 
Via The Motley Fool
Topics Animal Testing Artificial Intelligence
News headline image
WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
Topics Artificial Intelligence
News headline image
3 Growth Stocks to Invest $1,000 in Right Now ↗
Not every promising prospect is currently priced too richly relative to its risk. 
Via The Motley Fool
News headline image
Most active stocks in Thursday's session ↗
Stay updated with the latest market activity on Thursday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight. 
Via Chartmill
News headline image
Is Recursion Pharmaceuticals a Millionaire Maker? ↗
This is the only biotech stock to attract an investment from artificial intelligence (AI) giant Nvidia. 
Via The Motley Fool
Topics Artificial Intelligence Initial Public Offering
News headline image
Morgan Stanley, T1 Energy, Bunge Global, Bank of America And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
AI Agents Usher in a New Era of Pharmaceutical Discovery: Accelerating Cures to Market
The pharmaceutical industry stands on the precipice of a revolutionary transformation, driven by the burgeoning power of artificial intelligence (AI) agents. These sophisticated, autonomous systems are... 
Via TokenRing AI
Topics Artificial Intelligence Intellectual Property
News headline image
Absci's AI Revolution: A New Era for Drug Discovery or a Rocky Road Ahead?
Absci (NASDAQ: ABSI), a pioneer in AI-driven drug discovery, is making significant strides with its "Integrated Drug Creation™ Platform," promising to revolutionize how new medicines are brought to... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk ↗
Absci's AI drug development platform is compelling, and its pipeline is promising...but can the company overcome execution hurdles to live up to analyst hype? 
Via MarketBeat
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.